KRAS and BRAF mutational analyses in a phase II trial of first-line FOLFOXIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts)

被引：2
|
作者：
Salvatore, L. [1 ]
Loupakis, F. [1 ]
Fontanini, G. [2 ]
Cremolini, C. [1 ]
Stasi, I. [3 ]
Fabbri, A. [4 ]
Ciarlo, A. [5 ]
Granetto, C. [6 ]
Basolo, F. [2 ]
Falcone, A. [7 ]
机构：
[1] Univ Pisana, Azienda Osped, UO Oncol Med Univ 2, Ist Toscano Tumori, Pisa, Italy
[2] Univ Pisana, Azienda Osped, UO Anat Patol Sperimentale Univ, Pisa, Italy
[3] Azienda USL 6, UO Oncol Med, Ist Toscano Tumori, Livorno, Italy
[4] Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol Oncol Med, Rome, Italy
[5] Osped Misericordia & Dolce, UO Oncol Med, Prato, Italy
[6] Osped S Croce & Carle, UO ONcol Med, Cuneo, Italy
[7] Univ Pisa, Dipartimento Oncol Trapianti & Nuove Tecnol Med, Pisa, Italy
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71155-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：339 / 339
页数：1
相关论文
共 50 条
  • [31] PRELIMINARY EFFICACY, SAFETY AND OPERABILITY OF BEVACIZUMAB(BV) PLUS CAPECITABINE PLUS OXALIPLATIN (XELOX) AS FIRST-LINE THERAPY IN JAPANESE PATIENTS (PTS) WITH INITIALLY UNRESECTABLE METASTATIC COLORECTAL CANCER (MCRC)
    Yamaguchi, K.
    Boku, N.
    Kato, K.
    Komatsu, Y.
    Muro, K.
    Hamamoto, Y.
    Sato, A.
    Koizumi, W.
    Mizunuma, N.
    Takiuchi, H.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 130 - 130
  • [32] FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab (BV) in the first-line treatment of metastatic colorectal cancer (mCRC): A phase II study by the GONO group
    Falcone, A.
    Masi, G.
    Loupakis, F.
    Vasile, E.
    Ciarlo, A.
    Cavaciocchi, D.
    Amoroso, D.
    Puglisi, M.
    Fea, E.
    Brunetti, I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [33] First-line treatment of metastatic colorectal cancer (MCRC) with FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) in combination with bevacizumab (BV): A phase II study by the GONO group
    Masi, G.
    Loupakis, F.
    Baldi, G.
    Fornaro, L.
    Stasi, I
    Vasile, E.
    Cialo, A.
    Cavaciocchi, D.
    Di Leo, A.
    Puglisi, M.
    Ciprotti, M.
    Amoroso, D.
    Fea, E.
    Di Donato, S.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 26 - 26
  • [34] Effectiveness and Safety of Bevacizumab(BV) plus FOLFIRI as First-Line Metastatic Colorectal Cancer (mCRC) Treatment: ETNA Cohort Study
    Fourrier-Reglat, A.
    Rouyer, M.
    Benichou, J.
    Balestra, A.
    Bernard, M. A.
    Grelaud, A.
    Smith, D.
    Ravaud, A.
    Moore, N.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 : S28 - S28
  • [35] Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer
    Masaaki Miyo
    Takeshi Kato
    Takayuki Yoshino
    Takeharu Yamanaka
    Hideaki Bando
    Hironaga Satake
    Kentaro Yamazaki
    Hiroya Taniguchi
    Eiji Oki
    Masahito Kotaka
    Koji Oba
    Yoshinori Miyata
    Kei Muro
    Yoshito Komatsu
    Hideo Baba
    Akihito Tsuji
    [J]. BMC Cancer, 20
  • [36] Capecitabine (X), irinotecan (I) and bevacizumab (A) as first-line therapy for patients (PTS) with metastatic colorectal cancer (MCRC): Preliminary phase II study results
    Semir, Beslija
    Maja, Banjin
    Nadja, Paraganlija
    Timur, Ceric
    Anes, Pasic
    Berisa, Salkic
    Anes, Sosevic
    Nermina, Obralic
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 127 - 127
  • [37] Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer
    Miyo, Masaaki
    Kato, Takeshi
    Yoshino, Takayuki
    Yamanaka, Takeharu
    Bando, Hideaki
    Satake, Hironaga
    Yamazaki, Kentaro
    Taniguchi, Hiroya
    Oki, Eiji
    Kotaka, Masahito
    Oba, Koji
    Miyata, Yoshinori
    Muro, Kei
    Komatsu, Yoshito
    Baba, Hideo
    Tsuji, Akihito
    [J]. BMC CANCER, 2020, 20 (01)
  • [38] QUATTRO-II: A multicenter randomized trial comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Efficacy and safety analysis
    Kotaka, M.
    Bando, H.
    Satake, H.
    Kotani, D.
    Hamaguchi, T.
    Shiozawa, M.
    Ikumoto, T.
    Masuishi, T.
    Yasui, H.
    Kagawa, Y.
    Oki, E.
    Yamamoto, Y.
    Kawakami, H.
    Boku, S.
    Komatsu, Y.
    Taniguchi, H.
    Muro, K.
    Yamazaki, K.
    Misumi, T.
    Yoshino, T.
    Kato, T.
    Tsuji, A.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S68 - S68
  • [39] Prognostic genomic signatures in RAS/BRAF mutant (mut) metastatic colorectal cancer (mCRC) patients (pts) from the phase II study of NIVolumab (niv) plus FOLFOXIRI/Bevacizumab (bev) in first-line therapy of Advanced COloRectal cancer (NIVACOR- GOIRC-03-2018)
    Normanno, N.
    Damato, A.
    Abate, R. Esposito
    Tessitore, S.
    Bergamo, F.
    Antonuzzo, L.
    Nasti, G.
    Pietrantonio, F.
    Tonini, G.
    Latiano, T. P.
    Bordonaro, R.
    Rosati, G.
    Giommoni, E.
    Iachetta, F.
    Larocca, M.
    Maiello, E.
    Lonardi, S.
    Romagnani, A.
    Maglietta, G.
    Pinto, C.
    [J]. ANNALS OF ONCOLOGY, 2024, 35 : S50 - S51
  • [40] A phase II study of FOLFOXIRI plus bevacizumab (Bmab) as initial chemotherapy for patients (pts) with untreated metastatic colorectal cancer (mCRC): TRICC1414 (Be TRI)
    Yamada, Takeshi
    Nishina, Tomohiro
    Nasu, Junichiro
    Matsumoto, Toshihiko
    Yuasa, Yasuhiro
    Shiraishi, Takeshi
    Nagano, Hiroaki
    Moriyama, Ichiro
    Fujiwara, Toshiyoshi
    Miguchi, Masashi
    Yoshida, Ryosuke
    Nosaka, Kimiyasu
    Tanioka, Hiroaki
    Nagasaka, Takeshi
    Kurisu, Yasuro
    Kobayashi, Michiya
    Tsuchihashi, Kenji
    Inukai, Michio
    Kikuchi, Takashi
    Shinozaki, Katsunori
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
12345